BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Instructions to Plan for Your Teeth Substitution Methodology - 2CVS forecasts 2026 profit above estimates on strong performance
- 3Mummified cheetahs found in Saudi caves shed light on lost populations
- 4Malaysia To Revive Search for Missing Flight MH370
- 5The Meaning of Breaking the Pen's Nib in Death penalties
- Artemis II astronauts make long-distance call to the space station as they head home from the moon
- Israeli Chief of Staff declares new border with Gaza Strip
- The Best 10 Innovation Advancements of the Year
- Vote In favor of Your Favored Web-based Visual depiction Administration
- What to expect from the planets in 2026 — key dates and sky events
- New UPS distribution center in Taiwan doubles capacity, productivity
- Home Security Frameworks with Shrewd Elements
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- A hunger for new experiences Narratives: Motivating Travel and Experience
